IC
INBX

Ikarian Capital’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Ikarian Capital’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-85,800
Closed -$1.91M – 232
2022
Q1 		$1.91M Buy
85,800
+5,000
+6% +$128K 0.25% 71
2021
Q4 		$3.53M Buy
+80,800
New +$3.23M 0.53% 44

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ikarian Capital's INBX Position: Q3 2022 in Review

Ikarian Capital sold out of Inhibrx, Inc. Common Stock (INBX) in Q3 2022, closing a stake of 49,372 shares — an estimated $561K sold.

Ikarian Capital first reported a position in INBX in Q4 2020 and held it in 7 quarters. The position peaked at $9.65M in Q3 2021. 102 funds tracked by Wall St. Rank hold INBX as of Q3 2022.

  • Ikarian Capital reported no remaining Inhibrx, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Ikarian Capital sold 49,372 Inhibrx, Inc. Common Stock shares in Q3 2022, an estimated $561K.
  • Ikarian Capital first reported a position in Inhibrx, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
  • Ikarian Capital's Inhibrx, Inc. Common Stock position peaked at $9.65M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.